← back to search

Julio A. Camarero

University of Southern California · US
Area of research
Molecular Biology · Plant Science
Research interest
Research interests include Biochemical and Structural Characterization, Glycosylation and Glycoproteins Research, Chemical Synthesis and Analysis, and Phytoplasmas and Hemiptera pathogens.
h-index
44
citations
7,543
works
144
NIH funding
primary concept
email

Recent publications

Resistance is futile: targeting multidrug-resistant bacteria with <i>de novo</i> Cys-rich cyclic polypeptides.
2023cited by 6position: contributordoi
Lipidation of a bioactive cyclotide-based CXCR4 antagonist greatly improves its pharmacokinetic profile in vivo.
2023cited by 2position: contributordoi
Using the Cyclotide Scaffold for Targeting Biomolecular Interactions in Drug Development.
2022cited by 11position: contributordoi
SARS-CoV-2 Nsp5 Demonstrates Two Distinct Mechanisms Targeting RIG-I and MAVS To Evade the Innate Immune Response.
2021cited by 97position: contributordoi
Engineered Cyclotides with Potent Broad in Vitro and in Vivo Antimicrobial Activity.
2021cited by 11position: contributordoi
Chemical Synthesis of a Potent Antimicrobial Peptide Murepavadin Using a Tandem Native Chemical Ligation/Desulfurization Reaction.
2021cited by 11position: contributordoi
Cover Feature: Engineered Cyclotides with Potent Broad in Vitro and in Vivo Antimicrobial Activity (Chem. Eur. J. 49/2021)
Chemistry – A European Journal 2021cited by 1position: contributordoi
Recombinant Expression of Cyclotides Using Expressed Protein Ligation.
2020cited by 5position: contributordoi
The Potential of the Cyclotide Scaffold for Drug Development.
2019cited by 35position: contributordoi
Biotechnological Applications of Protein Splicing.
2019cited by 34position: contributordoi
Using backbone-cyclized Cys-rich polypeptides as molecular scaffolds to target protein-protein interactions.
2019cited by 21position: contributordoi
Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature
Natural Product Reports 2012cited by 2,074position: middledoi
Design of a Novel Cyclotide-Based CXCR4 Antagonist with Anti-Human Immunodeficiency Virus (HIV)-1 Activity
Journal of Medicinal Chemistry 2012cited by 125position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

· 5 papers (2019–2023) · 1 papers (2012–2012)Nouri Neamati · Michigan Medicine1 papers (2012–2012)Frauke Christ · KU Leuven1 papers (2012–2012) · 1 papers (2012–2012)Zeger Debyser · KU Leuven1 papers (2012–2012)Helen Ha · Washington University in St. Louis1 papers (2012–2012) · 1 papers (2012–2012)